Accelerating the Development of Viral Vector Therapeutics
Adeno-associated virus (AAV)-based therapies offer the unique ability to target specific tissues at the genetic level, enabling the treatment—and in some cases potential correction—of diseases that were previously difficult to address with conventional methods. As AAV programs advance from research to manufacturing, the ability to efficiently separate, characterize, and monitor critical quality attributes—such as empty versus full capsids—becomes essential.
Combining high-performance chromatography resin, advanced HPLC columns, and sensitive detection systems enables reliable separation and characterization of AAVs.
